Zuzanna Agnieszka Pawlus

Ms. Zuzanna Agnieszka Pawlus

orcid

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2025 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
WKWiktor Kruczek
Wiktor Kruczek
AFAleksandra Fratczak
Aleksandra Fratczak
ILIga Litwińska-Inglot
Iga Litwińska-Inglot
KPKarina Polak
Karina Polak
ZPZuzanna Agnieszka Pawlus
Zuzanna Agnieszka Pawlus
BMBartosz Miziołek
Bartosz Miziołek
Background: Bimekizumab, secukinumab, and ixekizumab are IL-17-targeting biologics approved for the treatment of moderate-to-severe plaque psoriasis. While secukinumab and ixekizumab selectively inhibit IL-17A, bimekizumab targets both IL-17A and IL-17F, potentially providing greater anti-inflammatory efficacy. This study aimed to compare the real-world effectiveness, safety, and tolerability of these agents in a Polish dermatology center between 2019 and 2024. Methods: We conducted a retrospective analysis of 98 patients meeting at least one of the following criteria: PASI ≥ 10, BSA ≥ 10, DLQI ≥ 10, or involvement of special areas with inadequate response or contraindications to ≥2 systemic therapies. Patients with prior exposure only to IL-17 inhibitors were excluded. PASI, BSA, and DLQI scores were recorded at baseline, week 4, and week 12. Due to differences in dosing schedules, outcomes were aligned using standardized timepoints and exponential modeling of continuous response trajectories. Mixed-effects ANOVA was used to assess the influence of baseline factors (age, BMI, PsA status) on treatment outcomes. Adverse events were documented at each monthly follow-up visit. Results: Bimekizumab showed the greatest effect size for PASI reduction (Hedges’ g = 3.662), followed by secukinumab (2.813) and ixekizumab (1.986). Exponential modeling revealed a steeper response trajectory with bimekizumab (intercept = 0.289), suggesting a more rapid PASI improvement. The efficacy of bimekizumab was particularly notable in patients who were previously treated with IL-23 inhibitors. All three agents demonstrated favorable safety profiles, with no serious adverse events or discontinuations. The most frequent adverse events were mild and included upper respiratory tract infections and oral candidiasis. Conclusions: This real-world analysis confirmed that IL-17 inhibitors effectively improved PASI, BSA, and DLQI scores in moderate-to-severe psoriasis. Bimekizumab demonstrated the most rapid early improvements and a higher modeled likelihood of complete clearance, without significant differences at week 12. All agents were well tolerated, underscoring the need for further individualized, large-scale studies.

7 September 2025 in Measurement
Verified
Journal Article
Closed access
ZPZuzanna Agnieszka Pawlus
Zuzanna Agnieszka Pawlus
WKWiktor Kruczek
Wiktor Kruczek
Rafał ReizerRafał Reizer
Rafał Reizer
Andrzej DzierwaAndrzej Dzierwa
Andrzej Dzierwa
AFAleksandra Frątczak
Aleksandra Frątczak
BBBeata Bergler-Czop
Beata Bergler-Czop

5 September 2025 in Biomedicines
Verified
Journal Article
Open access
PDF file
ZPZuzanna Agnieszka Pawlus
Zuzanna Agnieszka Pawlus
PMPatryk Mosiołek
Patryk Mosiołek
KBKarolina Bierć
Karolina Bierć
APAleksandra Pilśniak
Aleksandra Pilśniak
AJAgata Janoska-Gawrońska
Agata Janoska-Gawrońska
MHMichał Holecki
Michał Holecki
Background: Vitamin D plays a crucial role in numerous physiological systems, including the muscular, immune, and endocrine systems, as well as calcium and bone homeostasis. Vitamin D deficiency, a global health problem affecting billions of people, is associated with adverse health outcomes and can serve as a marker for health status, disease severity, and length of hospital stay (LOS). Nutritional supplementation has been shown to be highly beneficial and is strongly recommended. Methods: In this study, the medical records of 834 hospitalized patients were retrospectively analyzed, with a focus on 25-hydroxyvitamin D [25(OH)D] levels. The patients were divided into groups based on serum vitamin D levels: deficient, suboptimal, adequate, and high. Correlations between vitamin D levels, LOS, laboratory parameters, comorbidities, seasonal variations, medical diagnosis of deficiency, and supplementation were examined. Results: Vitamin D deficiency was common and associated with a longer LOS. Women had higher vitamin D levels than men. No seasonal variation was observed. Only 14% of the patients took supplements before hospitalization, and 61% of the patients with vitamin D deficiency received supplementation. Conclusions: Routine vitamin D screening, tailored supplementation, and increased public awareness are essential to reduce hospitalizations, improve treatment outcomes, and promote independence among at-risk groups.

29 November 2024 in Annales Academiae Medicae Silesiensis
Verified
Journal Article
Open access
SGSzymon Gawęda
Szymon Gawęda
MRMikołaj Rycerski
Mikołaj Rycerski
ZPZuzanna Agnieszka Pawlus
Zuzanna Agnieszka Pawlus
ADAnna Danel
Anna Danel
AOAleksandra Oraczewska
Aleksandra Oraczewska
SSSzymon Skoczynski
Szymon Skoczynski
Wprowadzenie: Bronchofiberoskopia (fiberoptic bronchoscopy – FOB) to małoinwazyjna procedura medyczna, powszechnie używana w diagnostyce i leczeniu chorób układu oddechowego. Zabieg jest na ogół dobrze tolerowany i istnieje niewiele przeciwwskazań do jego stosowania. Podczas FOB wprowadzany bronchofiberoskop powoduje ostre zwężenie dróg oddechowych, mogące skutkować rozwinięciem się lub zaostrzeniem niewydolności oddychania (respiratory failure – RF). Z tego powodu pacjenci z RF mogą zostać zdyskwalifikowani z zabiegu bronchoskopowego. Nieinwazyjne techniki wspomagania oddechu, takie jak donosowa terapia wysokoprzepływowa (high-flow nasal cannula – HFNC) oraz maska do wentylacji nieinwazyjnej (non-invasive ventilation – NIV), są cenionymi metodami wsparcia układu oddechowego u pacjentów z RF, jednak możliwości ich wykorzystania u pacjentów poddawanych FOB są wciąż niejasne.Opis przypadków: W opracowaniu opisano przypadki pięciu pacjentów poddanych bronchoskopii z różnych wskazań. W dwóch przypadkach rozpoznano guza krtani, w jednym obecność ciała obcego powikłanego nawracającymi zapaleniami płuc, u jednej pacjentki zapalenie płuc związane z przedłużoną intubacją, a w ostatnim przypadku RF po udarze niedokrwiennym mózgu. W każdym przypadku podczas FOB zastosowano wsparcie oddychania w postaci HFNC lub NIV z powodu wysokiego ryzyka rozwoju lub zaostrzenia RF. Parametry HFNC i NIV ustawiono zgodnie z założeniami dwóch trwających obecnie badań randomizowanych.Wnioski: Metody wsparcia oddechowego, takie jak HFNC oraz NIV, są obiecującymi metodami u pacjentów z wysokim ryzykiem rozwinięcia się RF podczas FOB.

1 January 2024 in Journal of Health Study and Medicine
Verified
Journal Article
Open access
PDF file
MKMagdalena Kwiatkowska
Magdalena Kwiatkowska
GMGabriela Majta
Gabriela Majta
AŻAleksandra Żabińska
Aleksandra Żabińska
NKNatalia Kozłowska
Natalia Kozłowska
WKWeronika Komala
Weronika Komala
AMAnna Mandecka
Anna Mandecka
Background: Binge eating disorder (BED) is currently the most common form of an eating disorder. BED is characterized by the consumption of large amounts of food in a short period of time, in a manner not controlled by the sick person. Its etiology is not fully known, but it is assumed that the development of the disorder results from psychological, social, and biological factors. Objectives: The aim of the study is to systematize information about BED and raise awareness among the public and health professionals about the issue. Material and methods: This paper is based on a comprehensive review of scientific research conducted worldwide. Our conclusions are informed by the latest reports that explore various aspects of the daily lives of patients with BED. Results: BED is classified into varying degrees of severity, depending on the number of bouts of eating per week. The gold standard for diagnosis is a structured psychological assessment. BED often co-exists with overweight and obesity, increasing the risk of somatic and psychosocial complications. Dietary education is the basis of therapy, and psychotherapy is the first line of treatment. Pharmacotherapy, which includes lisdexamfetamine and antidepressant, antiepileptic, psychostimulant, and anti-obesity drugs, is an important support. Forming proper eating habits is key in BED prevention. Conclusions: The multifaceted nature of BED, which affects many aspects of patients’ lives, reduces their quality of life. Increasing social awareness, health education, and countering the stigma on those affected by this disorder are also key.

30 December 2024 in Journal of Social Researches
Verified
Journal Article
Closed access
SRSusana Ruíz-Valdés
Susana Ruíz-Valdés
JRJuan Alberto Ruíz-Tapia
Juan Alberto Ruíz-Tapia
ZPZuzanna Agnieszka Pawlus
Zuzanna Agnieszka Pawlus
The objective of this research is to develop a comprehensive methodology to effectively implement Open Innovation for Competitiveness and Development (ICD) in traditional companies. The aim is to design a methodology that considers the particularities and unique challenges that traditional companies face when adopting open innovation practices. The contribution involves the creation of a structured and systematic approach that covers the stages of the ICD adoption process, from the identification of opportunities to the execution and evaluation of open innovation initiatives.